Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

Recent & Breaking News (GREY:COTQF)

COTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent Protection

Marketwired November 13, 2013

Critical Outcome Technologies Announces Warrant Expiry Date Amendment

Marketwired October 29, 2013

Critical Outcome Technologies Grants Stock Options

Marketwired October 15, 2013

Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum

Marketwired October 3, 2013

Critical Outcome Technologies Reports Fiscal 2014 First Quarter Results

Marketwired September 27, 2013

Critical Outcome Technologies Announces Warrant Term Amendments

Marketwired September 11, 2013

Critical Outcome Technologies Files Revised 2013 Annual Financial Statements Due to Clerical Error

Marketwired September 4, 2013

Critical Outcome Technologies Completes Final Tranche of Private Placement

Marketwired August 30, 2013

Critical Outcome Technologies Completes Private Placement

Marketwired August 28, 2013

Critical Outcome Technologies Reports Year-End Financial and Operating Results

Marketwired August 27, 2013

Critical Outcome Technologies Inc. Completes Financing

Marketwired August 16, 2013

Critical Outcome Technologies Inc. Completes Financing

Marketwired June 24, 2013

Critical Outcome Technologies Inc. Completes Financing

Marketwired June 24, 2013

Critical Outcome Technologies Inc.: Promising Advance for Many Common Cancers

Marketwired June 11, 2013

Critical Outcome Technologies Inc.: Promising Advance for Many Common Cancers

Marketwired June 11, 2013

Critical Outcome Technologies Inc. Completes Financing

Marketwired June 3, 2013

Critical Outcome Technologies Inc. Completes Financing

Marketwired June 3, 2013

Artificial Intelligence-Based Technology Yielding Positive Results in Drug Discovery Collaborations

Marketwired May 6, 2013

Artificial Intelligence-Based Technology Yielding Positive Results in Drug Discovery Collaborations

Marketwired May 6, 2013

Additional U.S. Patents for Lead Cancer Drug Candidate Strengthen Critical Outcome's Investment Proposition

Marketwired April 26, 2013